Cargando...

Antimyelin antibody in multiple sclerosis: no change during immunosuppression

We studied retrospectively levels of antimyelin antibody in a group of 13 multiple sclerosis patients who underwent a clinical trial of long-term, high dose (2.0-4.5 mg/kg/day) azathiaprine therapy. In apparent contrast with collagen vascular disease associated with antitissue antibody, azathiaprine...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wilkerson, L. D., Lisak, R. P., Zweiman, B., Silberberg, D. H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 1977
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC492860/
https://ncbi.nlm.nih.gov/pubmed/599363
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!